Eastern Angels investors back health-tech company Stride
Olympic medallist turned health tech entrepreneur Andrew Steele has raised nearly £5m ahead of the US launch of his health monitoring venture, Stride.
Steele – part of the Team GB 4 x 400m relay squad awarded bronze in Beijing 2008 – co-founded genetic testing firm DNAfit and sold it to David Beckham-backed global giant Prenetics for a reported $10m in 2018.
Stride offers holistic health monitoring encompassing DNA, gut and blood tests as well as consultation and supplements and in its latest £4.6m funding round attracted investment from Innovate UK and Morgan Stanley Inclusive, Sustainable Ventures and members of Eastern Angels.
Andrew pitched to Eastern Angels in June 2026 and immediately impressed the group with not only his drive and knowledge of the sector but also the impressive team he has built and longterm vision of improving health outcomes across the world.
Samantha Graham, Managing Director, Eastern Angels commented “Stride is exactly the kind of ambitious, high-growth company our members want to back — a proven founder, a large and fast-growing market, and a genuinely differentiated product. It's also a homegrown East of England business, which makes it a natural fit for our network. We're delighted to support Stride at this stage and look forward to watching the team scale this exciting business.”
The seed funding will be used to expand Stride’s product range, with a multi-source biological age test in development, and launch its Stride One membership in the US.
Capital at risk. Past performance does not guarantee future results.
Comments